Recurrent Malignant Mesothelioma Clinical Trial
Official title:
Phase II Study of GW786034 in Patients With Malignant Pleural Mesothelioma
This phase II trial is studying the side effects and how well pazopanib works in treating patients with malignant pleural mesothelioma. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
PRIMARY OBJECTIVES:
I. Determine the effect of pazopanib hydrochloride on the proportion of patients with
malignant pleural mesothelioma who are progression-free at 6 months based on the RECIST
criteria.
II. Determine the clinical toxicities of this drug in this patient population.
SECONDARY OBJECTIVES:
I. Determine the objective tumor response status in these patients as measured by the RECIST
criteria or the modified RECIST criteria.
II. Determine the response rate in patients treated with this drug. III. Determine the
effect of this drug on overall survival and time to progression in these patients.
IV. Assess predictive markers of activity of this drug in these patients. V. Assess
serologic markers of target inhibition by this drug in these patients.
VI. Determine the clinical toxicities of this drug in this patient population.
OUTLINE: This is a multicenter study.
Patients receive oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats
every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
Blood is collected at baseline and prior to each course of therapy and analyzed for markers
of angiogenesis.
After completion of study therapy, patients are followed every 3 months.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00025207 -
Gefitinib in Treating Patients With Malignant Mesothelioma
|
Phase 2 | |
Completed |
NCT00107432 -
Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
|
Phase 2 | |
Completed |
NCT00027703 -
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma
|
Phase 2 | |
Terminated |
NCT00028782 -
EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer
|
N/A | |
Recruiting |
NCT04213794 -
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients
|
Early Phase 1 | |
Completed |
NCT01503177 -
Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma
|
Phase 1 | |
Completed |
NCT00243074 -
S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT01126346 -
Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
|
N/A | |
Completed |
NCT00039182 -
Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung
|
Phase 2 | |
Withdrawn |
NCT01325753 -
Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body
|
N/A | |
Active, not recruiting |
NCT01064648 -
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
|
Phase 1/Phase 2 | |
Completed |
NCT00365053 -
PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
|
Phase 2 | |
Terminated |
NCT01861301 -
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
|
Phase 2 | |
Completed |
NCT00392444 -
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
|
Phase 2 | |
Completed |
NCT00309946 -
Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT00030498 -
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
|
Phase 1 | |
Recruiting |
NCT03420963 -
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT01105390 -
AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma
|
Phase 2 |